These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 27009956)

  • 1. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
    Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
    Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
    Vijayakumar G; Zamarin D
    Methods Mol Biol; 2020; 2058():133-154. PubMed ID: 31486036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in using Newcastle disease virus for tumor therapy: a review].
    Wu Y; Hao J; Li D
    Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes.
    de Graaf JF; van Nieuwkoop S; Bestebroer T; Groeneveld D; van Eijck CHJ; Fouchier RAM; van den Hoogen BG
    PLoS One; 2022; 17(2):e0263707. PubMed ID: 35139115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
    Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
    J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
    He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
    Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newcastle Disease Virus Establishes Persistent Infection in Tumor Cells
    Rangaswamy US; Wang W; Cheng X; McTamney P; Carroll D; Jin H
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28592535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
    Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
    Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
    Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
    Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
    Kalyanasundram J; Hamid A; Yusoff K; Chia SL
    Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
    Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
    Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newcastle disease virus as an oncolytic agent.
    Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
    Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
    Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
    Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
    Huang Z; Liu M; Huang Y
    Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
    Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
    Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.